Somnomed (ASX:SOM)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Somnomed.
RELATED STOCKHEAD STORIES
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade
Health Check: Long-suffering Mesoblast investors dare to dream
Rise and Shine: Everything you need to know before the ASX opens
Rise and Shine: Everything you need to know before the ASX opens
ASX Quarterlies: Junior techs and biotechs still thriving despite difficult conditions
ASX Quarterlies: Biotechs deliver strong performances for shareholders
ASX Health Stocks: Cochlear’s profit down 28pc in first half, as Estia’s aged care struggles with Omicron outbreak
ASX Health Stocks: Resapp gains on India COVID-19 trial, Atomo to supply HIV self-test in Australia
Directors’ Trades: As Nuix recovers from last month’s lows, one director made a $501,180 buy
ScoPo’s powerplays: It’s been ‘like a waterfall of information’ hitting us daily
SomnoMed taps tech for new board hires, posts full-year profit
Scopo’s powerplays: Investors love a result, until they don’t
What ASX investors should look for in a COVID-19 earnings season
